Coverage First, Price Controls Nineteen Years Later: Medicare Part D in 2003, the Ban on Negotiation and the Inflation Reduction Act's Drug Pricing Reforms
[Student Name]
University of Phoenix
HCS/455: Health Care Policy: The Past and the Future
Week 3 Assignment
[Instructor Name]
[Date]
The beneficiary described in the introduction is a composite written for a model paper.
A composite 72-year-old retired bus driver takes a blood thinner, two diabetes medicines and an inhaler. Before 2006, Medicare paid for his doctor visits and hospital stays but not for any of these drugs, and he would have paid for them himself unless he had retiree coverage. Today, Medicare Part D covers them, and beginning in 2025, his yearly out-of-pocket drug costs are capped. Those two changes arrived nineteen years apart, and the reasons for the gap say a great deal about how American health policy is made. This paper traces the expansion and the cost control that followed.
The Gap in Original Medicare
When Medicare was created in 1965, it covered hospital and physician care but not outpatient prescription drugs, which were a smaller part of medical care at the time. Over the following decades, drugs became central to treating chronic disease, and their costs rose. By the early 2000s, many older adults lacked drug coverage, and some skipped doses or went without medicines because of cost.
The 2003 Expansion
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created Part D, which began in January 2006. Its design reflected the politics of a Republican Congress and President who favored private markets. Rather than adding drug coverage directly to Medicare, the law delivered it through private plans, stand-alone drug plans and Medicare Advantage plans, which compete for enrollees and negotiate prices with manufacturers. Beneficiaries pay premiums, with substantial subsidies for those with low incomes.
The standard benefit included a deductible, cost sharing and a coverage gap, often called the donut hole, in which beneficiaries paid the full cost of drugs until their spending reached a catastrophic threshold. The law also contained a noninterference clause: it barred the Secretary of Health and Human Services from negotiating drug prices or requiring a formulary. Supporters argued that competing private plans would negotiate effectively and that government negotiation would amount to price controls that reduced innovation.
What the Expansion Achieved
Part D expanded drug coverage quickly. Economists studying the benefit's first years found that Part D lowered the prices paid for drugs commonly used by Medicare beneficiaries, particularly those who had previously lacked coverage, and increased their use of prescription drugs (Duggan & Scott Morton, 2010). Private plans did negotiate discounts, especially for drugs with competitors.
But the design left gaps. Plans had little power to negotiate prices for drugs without competitors, such as many newer brand-name and specialty drugs. The coverage gap left beneficiaries with high costs exposed. And with no cap on out-of-pocket spending above the catastrophic threshold, beneficiaries taking expensive specialty drugs could face thousands of dollars in costs each year.
Incremental Changes
The Affordable Care Act of 2010 began closing the coverage gap through manufacturer discounts and increased plan coverage, and by 2020 the gap had effectively closed for most beneficiaries. But spending on high-priced drugs continued to rise, and pressure grew for Medicare to negotiate prices directly.
The 2022 Cost Controls
The Inflation Reduction Act of 2022 made the largest changes to Part D since its creation. Four provisions stand out.
First, negotiation. The law directs Medicare to negotiate prices for a limited number of high-spending drugs that have been on the market for years without generic or biosimilar competition. The first ten Part D drugs were selected in 2023, and their negotiated prices took effect in 2026, with more drugs, including physician-administered Part B drugs, added in later years. Eligibility depends on time since approval, with small-molecule drugs becoming eligible sooner than biologics. Qureshi et al. (2024) applied the law's criteria to Medicare Part B and Part D spending data from 2016 to 2019 to estimate which drugs would have qualified, which shows how much the time-since-approval rules determine what can be negotiated.
Second, an out-of-pocket cap: beginning in 2025, Part D enrollees' annual out-of-pocket drug costs are capped at $2,000, indexed in later years.
Third, insulin: cost sharing for insulin covered by Medicare is capped at $35 a month.
Fourth, inflation rebates: manufacturers must pay rebates to Medicare when prices for drugs rise faster than general inflation.
What the Changes Mean for One Beneficiary
For the retired bus driver in the introduction, the reforms are concrete. His anticoagulant and one of his diabetes medicines were among the first ten drugs selected for negotiation, so the prices Medicare pays for them, and the cost sharing tied to those prices, fell when the negotiated prices took effect. His insulin-free diabetes regimen does not benefit from the insulin cap, but the $2,000 annual limit protects him if a new diagnosis requires an expensive specialty drug. Before the law, a single cancer drug could have cost him more than $10,000 a year out of pocket; now his exposure is capped.
Why the Gap Took So Long
The nineteen-year gap between expansion and cost control reflects several forces. The noninterference clause was part of the political bargain that passed Part D, and the pharmaceutical industry strongly opposed negotiation. Repeated proposals to allow negotiation failed. The eventual law passed through budget reconciliation, which requires only a simple majority in the Senate, and it limited negotiation to a small number of older drugs, a compromise that reduced opposition.
Open Questions
The reforms leave questions that policy will continue to address. Manufacturers argue that negotiation will reduce investment in new drugs, particularly small-molecule drugs, which become eligible for negotiation sooner; others argue that the effect will be modest. The out-of-pocket cap shifts costs to plans and Medicare, which may raise premiums. And legal challenges from manufacturers have tested the negotiation program in the courts.
Conclusion
Medicare's drug benefit shows a recurring pattern in U.S. health policy: coverage expansions are designed to pass, often by relying on private markets and limiting government power, and cost control comes later, when spending pressures build. Part D brought drug coverage to millions of older adults in 2006; the Inflation Reduction Act, nineteen years after the expansion was enacted, gave Medicare limited power to negotiate prices and protected beneficiaries from catastrophic costs.
References
Duggan, M., & Scott Morton, F. (2010). The effect of Medicare Part D on pharmaceutical prices and utilization. American Economic Review, 100(1), 590-607. https://doi.org/10.1257/aer.100.1.590
Inflation Reduction Act of 2022, Pub. L. No. 117-169, 136 Stat. 1818 (2022).
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Pub. L. No. 108-173, 117 Stat. 2066 (2003).
Qureshi, O., Ramachandran, R., & Ross, J. S. (2024). Medicare Part B and Part D drug eligibility for Center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: Estimates using 2016-2019 data. Journal of Pharmaceutical Policy and Practice, 17(1), Article 2312374. https://doi.org/10.1080/20523211.2024.2312374
How this HCS 455 Week 3 example is structured
The HCS/455 shelf page describes Week 3 as covering the major coverage expansions and the cost control that followed. The paper follows one benefit through both phases, because the design choices made to pass an expansion often shape the cost problems that come later. It explains what each law did, why it was designed that way and what the evidence shows, and it ends with the questions that remain open. Students search this week as HCS 455 Week 3, HCS455 Wk 3 or HCS/455 Wk 3; all three are the same assignment.
HCS/455 Week 3 questions, answered
What does HCS/455 Week 3 usually ask for?
The HCS/455 shelf describes Week 3 as covering the major coverage expansions and the cost control that followed. Many sections ask for a paper on a major policy such as Medicare, Medicaid, CHIP or the Affordable Care Act and on later efforts to control its costs.
What did the 2003 Medicare law do?
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created Medicare Part D, a voluntary outpatient prescription drug benefit delivered through private plans, starting in 2006. It included subsidies for low-income beneficiaries and a provision barring the federal government from negotiating drug prices.
What did the Inflation Reduction Act change for Medicare drugs?
It allowed Medicare to negotiate prices for a limited number of high-spending drugs, capped annual out-of-pocket drug costs for Part D enrollees starting in 2025, capped insulin cost sharing and required manufacturers to pay rebates when prices rise faster than inflation.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.